Get started
AbCellera Biologics Inc.AA

AbCellera Biologics Inc.

4.48USDR
+0.58+14.87%
At close at Jul 18, 23:59 GMT
USD
No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

ABCL chart


Full chart

ABCL upcoming earnings


Next report date
August 7
Report period
Q2 2025
EPS estimate
−0.14 USD
Revenue estimate
‪7.41 M‬ USD

Key stats


Market capitalization
‪1.34 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.57 USD
Net income (FY)
‪−162.86 M‬ USD
Revenue (FY)
‪28.83 M‬ USD
Shares float
‪223.95 M‬
Beta (1Y)
1.38

Employees


Employees (FY)
596
Change (1Y)
+10 +1.71%
Revenue / Employee (1Y)
‪48.38 K‬ USD
Net income / Employee (1Y)
‪−273.25 K‬ USD

About AbCellera Biologics Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Carl Lars G. Hansen
Website
abcellera.com
Headquarters
Vancouver
Founded
2012
FIGI
BBG00LLW2MF2
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Financials


Performance
‪−1,080.00%‬
‪−910.00%‬
‪−740.00%‬
‪−570.00%‬
‪−400.00%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−60.00 M‬‬
‪‪−40.00 M‬‬
‪‪−20.00 M‬‬
‪0.00‬
‪‪20.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−63.00 M‬‬
‪‪−42.00 M‬‬
‪‪−21.00 M‬‬
‪0.00‬
‪‪21.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−48.00 M‬‬
‪‪−32.00 M‬‬
‪‪−16.00 M‬‬
‪0.00‬
‪‪16.00 M‬‬
Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−70.00 M‬‬
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
‪‪210.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Aug 7, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−0.18‬
‪−0.14‬
‪−0.09‬
‪−0.04‬
‪0.00‬
Actual
Estimate

ABCL news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ABCL is 4.48 USD — it has increased by 14.87% in the past 24 hours. Watch AbCellera Biologics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange AbCellera Biologics Inc. stocks are traded under the ticker ABCL.
ABCL stock has fallen by −5.89% compared to the previous week, the month change is a 27.27% rise, over the last year AbCellera Biologics Inc. has showed a 32.15% increase.
We've gathered analysts' opinions on AbCellera Biologics Inc. future price: according to them, ABCL price has a max estimate of 17.00 USD and a min estimate of 5.00 USD. Watch ABCL chart and read a more detailed AbCellera Biologics Inc. stock forecast: see what analysts think of AbCellera Biologics Inc. and suggest that you do with its stocks.
ABCL reached its all-time high on Dec 11, 2020 with the price of 71.91 USD, and its all-time low was 1.89 USD and was reached on Apr 7, 2025. View more price dynamics on ABCL chart.
See other stocks reaching their highest and lowest prices.
ABCL stock is 20.30% volatile and has beta coefficient of 1.38. Track AbCellera Biologics Inc. stock price on the chart and check out the list of the most volatile stocks — is AbCellera Biologics Inc. there?
Today AbCellera Biologics Inc. has the market capitalization of ‪1.16 B‬, it has decreased by −2.74% over the last week.
Yes, you can track AbCellera Biologics Inc. financials in yearly and quarterly reports right on TradingView.
AbCellera Biologics Inc. is going to release the next earnings report on Aug 7, 2025. Keep track of upcoming events with our Earnings Calendar.
ABCL earnings for the last quarter are −0.15 USD per share, whereas the estimation was −0.14 USD resulting in a −10.19% surprise. The estimated earnings for the next quarter are −0.14 USD per share. See more details about AbCellera Biologics Inc. earnings.
AbCellera Biologics Inc. revenue for the last quarter amounts to ‪4.24 M‬ USD, despite the estimated figure of ‪7.24 M‬ USD. In the next quarter, revenue is expected to reach ‪7.41 M‬ USD.
ABCL net income for the last quarter is ‪−45.62 M‬ USD, while the quarter before that showed ‪−34.21 M‬ USD of net income which accounts for −33.36% change. Track more AbCellera Biologics Inc. financial stats to get the full picture.
No, ABCL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 19, 2025, the company has 596 employees. See our rating of the largest employees — is AbCellera Biologics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbCellera Biologics Inc. EBITDA is ‪−225.69 M‬ USD, and current EBITDA margin is −755.27%. See more stats in AbCellera Biologics Inc. financial statements.
Like other stocks, ABCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbCellera Biologics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbCellera Biologics Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbCellera Biologics Inc. stock shows the buy signal. See more of AbCellera Biologics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.